Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.

What Was Tested

The paper reports a study of Losartan, published as a randomized controlled trial.

The researchers aimed to assess the effect of the angiotensin II receptor blocker losartan on left ventricular hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

Patients and investigators were masked to assigned treatment.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and pilot.

Because people in this Losartan study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Losartan.

Some participants received a placebo instead of Losartan, giving a reference point.

It is described as a pilot, a small early test of whether a larger Losartan study would be practical.

The primary endpoint was change in left ventricular mass as assessed by cardiac magnetic resonance imaging (CMR) or CT.

The trial is registered with ClinicalTrials.gov, number NCT01447654.

What Was Measured

The subject headings attached to it are Angiotensin II Type 1 Receptor Blockers, Cardiomyopathy, Hypertrophic, Fibrosis, Heart Ventricles, Hypertrophy, Left Ventricular and Losartan.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Losartan.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: all human trials.